Dementia Care Facilities Still Lean on Sedating Drugs When Behavior Escalates
Marjorie Tingley’s story sits at the fault line between dementia care, staff safety, and medication risk. In late 2024, the 85-year-old resident of a Michigan memory care unit was described as hitting, kicking, and elbowing aides during intimate care tasks such as changing briefs, bathing, dressing, and toileting. Her sons were asked to authorize sedating medication after Vista Grande Villa concluded she had become a major safety threat.
The drug class at the center of the dispute carries a well-established warning. The FDA requires manufacturers to state that antipsychotic drugs increase the risk of death in older adults with Alzheimer’s disease and related dementias. Yet these medications remain widely used in long-term care, especially when agitation creates immediate danger for staff or other residents. A federal campaign that began in 2012 reduced use to some degree, but prescribing remains stubbornly common, and a recent JAMA analysis estimated that 1 in 4 Medicare beneficiaries with dementia are potentially inappropriately prescribed antipsychotics and other brain-altering medications that can provoke delirium, falls, and hospitalizations.
The tension is not abstract. It is a daily operational problem in facilities built around residents with damaged impulse control, poor recognition, and limited ability to communicate pain or fear. When those brain circuits fail, aggression may be a signal of infection, discomfort, hunger, or confusion rather than a character problem. In Marjorie Tingley’s case, the family repeatedly pushed for a search for reversible causes before accepting sedating medication.
Infection Workup, Emergency Transfers, and the Pressure to Medicate
Vista Grande’s behavior logs described a pattern of aggression in early December 2024. The facility wanted permission to sedate Tingley, but her sons asked first for a check for a urinary tract infection, which they said had triggered agitation before. A urine sample was collected, but the facility did not ensure laboratory testing for more than a week, and the sample had to be repeated. In the meantime, staff behavior escalated into repeated emergency calls and hospital trips.
A mental health evaluation at Henry Ford Jackson Hospital did not lead to involuntary hospitalization, but doctors confirmed a urinary tract infection and treated it with antibiotics. Even after that, Vista Grande said she could not return unless the family agreed to sedating medication. The family experienced the demand as coercive. One son recalled feeling as if his mother was being held “ransom” unless he approved the drug.
The case exposes a common and often uncomfortable dynamic in long-term care: facilities are expected to keep residents and workers safe, yet they may have limited ability to manage severe behavioral symptoms without medication. For people with advanced dementia, the physical setting itself can worsen agitation. Bathing, diaper changes, and dressing can feel invasive to someone who no longer understands the situation. Fear can quickly become defensive striking, and a cycle of restraint avoidance, emergency transfer, and sedative prescribing can follow.
A recent review of assisted living and nursing home practice makes the stakes plain. Although assisted living facilities do not provide round-the-clock skilled medical care, nearly half of the roughly 1 million people in them have Alzheimer’s disease or another dementia. In assisted living residents with dementia, antipsychotics were prescribed for an average of 13% of the time they lived in the facility, according to one 2023 study. Another analysis found that the federal campaign against overuse did not appear to meaningfully change prescribing trends in this population.
Lorazepam, Olanzapine, and the Cost of Choosing the Least-Bad Option
The Tingleys’ resistance did not end medication use; it changed which drugs were tried and how the family understood the tradeoffs. Vista Grande first gave Marjorie Tingley lorazepam, sold as Ativan, an anti-anxiety benzodiazepine. The label warns of dizziness, unsteadiness, weakness, and paradoxical reactions including agitation and rage. The drug also requires caution in patients with breathing problems, and Tingley had sleep apnea. After a week, facility workers gave mixed reports about whether the medication was calming her, and charting still described yelling and marked agitation.
The family later authorized a low dose of olanzapine, sold as Zyprexa, an antipsychotic approved for schizophrenia and bipolar disorder. The FDA black box warning states that the drug is not approved for dementia-related psychosis and increases death risk in older adults with those conditions. Eli Lilly, the manufacturer, paid a $1.4 billion criminal fine and civil settlement in 2009 over allegations of improper promotion for dementia use. Tingley’s sons were alarmed by the warning and worried about cardiac effects because she had atrial fibrillation. They agreed only to 2.5 milligrams daily, half the starting dose recommended by the manufacturer.
A medication that quiets one symptom can still worsen the overall clinical picture. In frail older adults, sedation may reduce striking or yelling while increasing falls, worsening confusion, suppressing respiration, or blunting the ability to participate in care. For families, the ethical calculus becomes brutal: accept the possibility of injury from untreated agitation, or accept the risks of chemical restraint-like treatment. For facilities, the incentive structure can tilt toward containment because behavior that threatens staff or other residents is immediately visible, while downstream drug harms may emerge later and at a different site of care.
An Eviction Notice Followed by More ER Trips
The conflict sharpened after four emergency department transfers. Vista Grande issued a 30-day eviction notice and sent Tingley to the hospital four more times while the family searched for a new placement. Her sons alleged in a pending lawsuit that the facility retaliated against them for disagreeing about care and that the ER transfers were part of that pressure campaign. Vista Grande denied the allegations and said in a legal filing that it sent her to the hospital because of the family’s refusal to allow treatment on site.
A Michigan circuit judge dismissed the negligence claim on legal grounds, but the remaining claims are headed toward trial early next year if mediation fails. Tingley moved to another facility and died less than two weeks later in January 2025. Her cause of death was plaque buildup in the brain, a hallmark of Alzheimer’s disease.
Her case shows how dementia care can fail at two levels at once: the underlying disease creates real danger, and the response to that danger can deepen the harm. Facilities may reach for drugs because they are familiar, fast, and administratively tidy. Families may see those same drugs as a threat to dignity, breathing, alertness, and survival. Between those positions sits a resident who may already be losing the ability to explain pain, fear, or distress in words.